CD33 and acute myeloid leukemia: Thus, we hypothesized that an adoptive cellular therapy approach targeting CD33+ AML cells with CD33-specific CAR-expressing-EBV-CTLs should provide all the benefits of a T-cell-based immune effect: tumor cell killing in particular via an intrinsic antibody-dependant cellular cytotoxic effect, cytokine release, improved tumor penetration, and prolonged persistence compared to monoclonal antibody therapy.